Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.
To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
The USD 14.6 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:
Therapeutic approach
- Gene augmentation
- Oncolytic therapy
- Immunotherapy
- Others
Type of gene therapy
- Ex vivo
- In vivo
- Type of vector used
- Adeno associated virus
- Adenovirus
- Herpes simplex virus
- Lentivirus
- Plasmid DNA
- Retrovirus
- Others
Key therapeutic areas
Autoimmune disorders
Cardiovascular diseases
Dermatological disorders
Genetic disorders
Hematological disorders
Metabolic disorders
Muscle-related diseases
Oncological disorders
Ophthalmic diseases
Others
Route of administration
- Intraarticular
- Intracerebellar
- Intradermal
- Intramuscular
- Intratumoral
- Intravenous
- Intravesical
- Intravitreal
- Subretinal
- Others
Key geographical regions
North America
Europe
- Asia-Pacific
The Gene Therapy Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:
- Abeona Therapeutics
- Advantagene
- Biogen
- bluebird bio
- Castle Creek Biosciences
- CG Oncology
- FerGene
- Freeline Therapeutics
- Gradalis
- Helixmith
- Inovio Pharmaceuticals
- Kolon TissueGene
- Krystal Biotech
- Lysogene
- Neurophth Therapeutics
- OncoSec Immunotherapies
- Orchard Therapeutics
- Pfizer
- Sangamo Therapeutics
- Spark Therapeutics
- uniQure Biopharma
VBL Therapeutics
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Gene Delivery Vectors
5. Regulatory Landscape and Reimbursement Scenario
6. Market Overview
7. Competitive Landscape
8. Marketed Gene Therapies
9. Key Commercialization Strategies
10. Late Stage (Phase II/III and Above) Gene Therapies
11. Emerging Technologies
12. Key Therapeutics Areas
13. Patent Analysis
14. Mergers and Acquisitions
15. Funding and Investment Analysis
16. Clinical Trial Analysis
17. Cost Price Analysis
18. Big Pharma Players: Analysis of Gene Therapy Related Initiatives
19. Demand Analysis
20. Market Forecast and Opportunity Analysis
21. Vector Manufacturing
22. Case Study: Gene Therapy Supply Chain
23. Conclusion
24. Interview Transcripts
25. Appendix 1: Tabulated Data
26. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
